

Table S1. Amplification primers (5'–3')

gene	forward	reverse
<i>TSLP</i>	CCG CCT ATG AGC AGC CAC	CCT CAG TAG CAT TTA TCT CAG
<i>IL-25</i>	GAG ATA TGA GTT GGA CAG AGA CTT GAA	CCA TGT GGG AGC CTG TCT GTA
<i>IL-33</i>	GAA GAA CAC AGC AAG CAA AGC	TAC CAA AGG CAA AGC ACT CC
<i>CCL4</i>	CTC CTC ATG CTA GTA GCT GCC TTC	GGT GTA AGA AAA GCA GCA GGC GGT
<i>CCL5</i>	GTT GCA CCA AGC TAT GCA GGT	GCA GAA GCG TTT GGC AAT GT
<i>CCL11</i>	CCA CAC TGA AGG TCT CCG CA	TCT CTA GTC GCT GAA GGG GT
<i>CCL26</i>	ACT CCG AAA CAA TTG TGA CTC AGC TG	GTA ACT CTG GGA GGA AAC ACC CTC TCC
<i>TSLPR</i>	ATA CTC CAG GAC CAA CCT GAC	ACA CGT CAC CGT CAC TGC ATC
<i>TLR3</i>	GGA TAG CTC TCC TTC ACC ATT C	GAC CCT CCA ACA TGT CAT CAT
<i>CCR5</i>	CCC AGT GCA CAC AAG TGT AGG TAT C	GCT CAA GGC AGC TTA TTT CCA A
<i>ICAM-1</i>	CTG CAG ACA GTG ACC ATC	GTC CAG TTT CCC GGA CAA
<i>GAPDH</i>	TTC ACC ACC ATG GAG AAG GC	AGG AGG CAT TGC TGA TGA TCT

Table S2. Characteristics of patients treated with dupilumab (n=19)

Age (years)	55.2 ± 14.9	FENO (ppb)	70.5 ± 44.7
Gender (M/F)	11/8	Lund-Mackay scale	14.5 ± 5.9
Body Mass Index (kg/m ²)	22.4 ± 3.3	Polyp score	4.9 ± 2.3
NSAID intolerance	7	JESREC score	15.9 ± 1.0
Smoking status (never/ex)	14/5	FEV ₁ (%predicted)	83.2 ± 19.8
ESS history (Y/N)	17/2	FEF ₂₅₋₇₅ (%predicted)	57.5 ± 38.0
Total IgE (IU/mL)	741 ± 797	FVC (%predicted)	96.3 ± 10.8
Positive RAST (none/single/multi)	5/3/11	Asthma exacerbation (per year)*	1.2 ± 1.8
Eosinophils (/μL) [peak value]	446 ± 369 [895 ± 528]		
Treatment			
Inhaled corticosteroids (μg)**	1047 ± 176	Anti-histamine	11
Long-acting β ₂ -adrenergic agonist	19	Inhaled nasal corticosteroids	14
Long-acting muscarinic antagonist	8	Oral corticosteroids	1
Leukotriene receptor antagonist	12	Low-dose macrolide	2

ESS: endoscopic sinus surgery; FENO = fractionated exhaled nitrogen oxide; FEF₂₅₋₇₅: forced expiratory flow between 25% and 75% of vital capacity; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; JESREC: Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis. *A clinically significant exacerbation defined as any worsening of asthma considered by the treating physician to require systemic corticosteroids. ** Equivalent doses of fluticasone propionate. Values are number of subjects and mean ± standard deviation.